ImmunityBio, Inc.
IBRX
Peringkat dalam Saham
#2232
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Harga Saham
$8.55
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$9.06B
Perubahan (1 hari)
-6.84%
Perubahan (1 tahun)
249.08%
Negara
US
Perdagangan ImmunityBio, Inc. (IBRX)
Kategori
Healthcare
Laba untuk ImmunityBio, Inc. (IBRX)
Laba pada Jun 2026 TTM: $-992.58M
Menurut laporan keuangan terbaru dari ImmunityBio, Inc., laba saat ini perusahaan adalah $-992.58M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-583.89M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-417.29M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk ImmunityBio, Inc. dari 2013 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $-992.58M | 139.96% |
| 2024 | $-413.65M | -29.16% |
| 2023 | $-583.89M | 39.93% |
| 2022 | $-417.29M | 19.28% |
| 2021 | $-349.84M | 54.77% |
| 2020 | $-226.03M | 243.07% |
| 2019 | $-65.89M | -31.89% |
| 2018 | $-96.73M | -0.19% |
| 2017 | $-96.92M | -20.16% |
| 2016 | $-121.38M | -48.82% |
| 2015 | $-237.18M | 3,718.05% |
| 2014 | $-6.21M | 203.62% |
| 2013 | $-2.05M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| $5.27B | -631.43% |
US
|
|
| $-3.09B | 211.01% |
US
|
|
| $-4.02B | 304.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -296.52% |
NL
|
